Product Information
FENOFIBRATE 134 MG CAPSULE is a generic product labeled by Glenmark Pharmaceuticals Inc., USA, priced at $0.1192 per EA under NDC 68462058101. Its NADAC has been published 491 times since May 10, 2017.
FDA first approved this application on Apr 7, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
134 mg/1
Manufacturer
Glenmark Pharmaceuticals Inc., USANDC
68462058101
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
FENOFIBRATEApproval Type
Generic (ANDA)
FDA Application
ANDA205566FDA Approved
4/7/2017
TE Code
AB
On Market Since
4/7/2017
Pharmacological Classes
Price Statistics
The NADAC for FENOFIBRATE 134 MG CAPSULE has been published 491 times since May 10, 2017, and over the history we have for it it has declined 88.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1192 per EA |
|---|---|
| All-time high | $1.0448 (May 10, 2017) |
| All-time low | $0.1020 (Nov 20, 2024) |
| 52-week high | $0.1338 |
| 52-week low | $0.1101 |
| Median price | $0.1730 |
| Average price | $0.2917 |
| Largest weekly change | +38.9% (Sep 23, 2020) |
| Weeks tracked | 491 |
| Tracking since | May 10, 2017 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 9% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Glenmark Pharmaceuticals Inc., USA manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
fenofibrate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Peroxisome Proliferator Receptor alpha Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FENOFIBRATE 134 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for FENOFIBRATE 134 MG CAPSULE, manufactured by Glenmark Pharmaceuticals Inc., USA, is $0.1192 per EA (NDC 68462058101), effective Sep 30, 2026.
How has the price of FENOFIBRATE 134 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for FENOFIBRATE 134 MG CAPSULE has declined 88.6%. It has been tracked across 491 weekly CMS publications since May 10, 2017.
What are the highest and lowest recorded NADAC prices for FENOFIBRATE 134 MG CAPSULE?
Since May 10, 2017, the NADAC for FENOFIBRATE 134 MG CAPSULE has ranged from a low of $0.1020 (Nov 20, 2024) to a high of $1.0448 (May 10, 2017), with a median of $0.1730 per EA.
Are there cheaper alternatives to FENOFIBRATE 134 MG CAPSULE?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, FENOFIBRATE 134 MG CAPSULE, is $0.1089 per EA — about 9% below FENOFIBRATE 134 MG CAPSULE.
Who manufactures FENOFIBRATE 134 MG CAPSULE?
FENOFIBRATE 134 MG CAPSULE (NDC 68462058101) is labeled by Glenmark Pharmaceuticals Inc., USA, and CMS classifies it as a generic product.